Trastuzumab-associated cardiotoxicity (Q34867708)

5 August 2017

1 reference

title

Trastuzumab-associated cardiotoxicity (English)

1 reference

5 August 2017

Deborah L Keefe

1

1 reference

PubMed ID

12237930

5 August 2017

language of work or name

English

0 references

publication date

1 October 2002

1 reference

5 August 2017

1 reference

5 August 2017

95

1 reference

5 August 2017

1592-1600

1 reference

5 August 2017

7

1 reference

Structure-function relationships for the EGF/TGF-alpha family of mitogens

5 August 2017

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10854

Neuregulins in development

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10854

Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10854

Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10854

Pathologic findings from the National Surgical Adjuvant Breast and Bowel Project: prognostic significance of erbB-2 protein overexpression in primary breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10854

The long term prognostic significance of c-erbB-2 in primary breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10854

Prognostic significance of HER-2 oncoprotein expression in breast cancer: a 30-year follow-up

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10854

Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10854

Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10854

Phase II study of receptor-enhanced chemosensitivity using recombinant humanized anti-p185HER2/neu monoclonal antibody plus cisplatin in patients with HER2/neu-overexpressing metastatic breast cancer refractory to chemotherapy treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10854

Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10854

Cardiac toxicity of trastuzumab (Herceptin): implications for the design of adjuvant trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10854

Weekly trastuzumab and paclitaxel therapy for metastatic breast cancer with analysis of efficacy by HER2 immunophenotype and gene amplification.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10854

Clinical activity of trastuzumab and vinorelbine in women with HER2-overexpressing metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10854

Outcome of clinical congestive heart failure induced by anthracycline chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10854

Requirement for neuregulin receptor erbB2 in neural and cardiac development

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10854

Stress pathways and heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10854

Risk factors for doxorubicin-induced congestive heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10854

Phase II trial of high-dose liposome-encapsulated doxorubicin with granulocyte colony-stimulating factor in metastatic breast cancer. TLC D-99 Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10854

Early detection of anthracycline induced cardiotoxicity in asymptomatic patients with normal left ventricular systolic function: autonomic versus echocardiographic variables

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10854

7 January 2021

Doxorubicin-induced cardiomyopathy

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10854

7 January 2021

Phase II trial of liposome-encapsulated doxorubicin, cyclophosphamide, and fluorouracil as first-line therapy in patients with metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10854

7 January 2021

Trastuzumab and breast cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10854

7 January 2021

Identifiers

DOI

10.1002/CNCR.10854

1 reference

5 August 2017

1 reference

PubMed ID

12237930